Orion publishes Financial Statement Release for 2023 and holds a webcast on 13 February 2024
29 Enero 2024 - 7:00AM
Orion publishes Financial Statement Release for 2023 and holds a
webcast on 13 February 2024
ORION CORPORATION PRESS RELEASE 29 January 2024 at 15.00 EET
Orion publishes Financial Statement Release for 2023 and
holds a webcast on 13 February 2024
Orion will publish Financial Statement Release for 2023 on
Tuesday, 13 February 2024 at approximately 12.00 noon EET. The
release and related presentation material will be available on the
company’s website at www.orion.fi/en/investors after
publishing.
Webcast and conference call
A webcast and a conference call for analysts, investors and
media representatives will be held on Tuesday, 13 February 2024 at
13.30 EET.
A link to the live webcast is available on Orion's website
at www.orion.fi/en/investors. A recording of the event will be
available on the website later the same day.
Confenrence call can be joined by registering through the
following link:
https://palvelu.flik.fi/teleconference/?id=5008942
Phone numbers and the conference ID to access the conference
will be provided after the registration. In case you would like to
ask a question during the conference, please dial *5 on your
telephone keypad to enter the question queue.
Questions can also be presented in writing through the question
form of the webcast.
Silent period
The silent period preceding the publication is ongoing and
continues until the disclosure.
Contact
person:Tuukka Hirvonen, Investor Relations, Orion
Corporationtel. +358 10 426 2721
Publisher:Orion
CorporationCommunicationsOrionintie 1A, FI-02200 Espoo,
Finlandwww.orion.fi
Orion is a globally operating Finnish pharmaceutical company – a
builder of well-being. We develop, manufacture and market human and
veterinary pharmaceuticals and active pharmaceutical ingredients.
Orion has an extensive portfolio of proprietary and generic
medicines and self-care products. The core therapy areas of our
pharmaceutical R&D are oncology and pain. Proprietary products
developed by Orion are used to treat cancer, neurological diseases
and respiratory diseases, among others. Orion's net sales in 2022
amounted to EUR 1,341 million and the company had about 3,500
employees at the end of the year. Orion's A and B shares are listed
on Nasdaq Helsinki.
Orion (BIT:1ORNBV)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Orion (BIT:1ORNBV)
Gráfica de Acción Histórica
De May 2023 a May 2024